Milical Tablet

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Active ingredient:

CALCIUM CITRATE; VITAMIN D3 GRANULES TYPE 850

Available from:

Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd.

INN (International Name):

CALCIUM CITRATE; VITAMIN D3 GRANULES TYPE 850

Units in package:

30Tablet Tablets

Manufactured by:

GLENMARK PHARMACEUTICALS LTD

Summary of Product characteristics

PANTONE
BLACK PROCESS C
SUPERSEDES
ARTWORK CODE:
PE33869
PANTONE SHADE
ICONGRAPHICS CODE:
PHARMACODE:
SAME SIZE ARTWORK
LEAFLET SIZE : 88 mm x 186 mm
For the use only of a Registered Medical Practitioner or a Hospital or
a Laboratory.
Milical
Milical
TT
AA
BB
LL
EE
TT
SS
SAME SIZE ARTWORK
LEAFLET SIZE : 88 mm x 186 mm
MILICAL relatively carries lower risk for the development of oxalate
stones in the susceptible
lithogenic population. Calcium citrate administration has not been
demonstrated to interfere with
the absorption of iron.
Excessive
intake
of
vitamin
D
leads
to
the
development
of
hyperphosphataemia
or
hypercalcaemia.
Associated
effects
of
hypercalcaemia
include
hypercalciuria,
ectopic
calcification, and renal and cardiovascular damage . Symptoms of
overdosage include anorexia,
lassitude, nausea and vomiting, constipation or diarrhoea, polyuria,
nocturia, sweating, headache,
thirst, somnolence, and vertigo. Interindividual tolerance to vitamin
D varies considerably; infants
and children are generally more susceptible to its toxic effects. The
vitamin should be withdrawn if
toxicity occurs. It has been stated that vitamin D dietary
supplementation may be detrimental in
persons already receiving an adequate intake through diet and exposure
to sunlight, since the
difference between therapeutic and toxic concentrations is relatively
small. Skin irritation or contact
dermatitis has been reported with topical preparations..
PRECAUTIONS / WARNINGS
A milical tablet is to be taken as per the direction in pregnant and
breast feeding women.
Arteriosclerosis - potential exacerbation related to persistent
hypercalcemic effects during
therapeutic use.
Cardiac conditions - potential exacerbation related to persistent
hypercalcemic effects during
therapeutic use
Concurrent use of calcium-containing preparations, other vitamin
D-containing preparations or
vitamin D analogs, or thiazide diuretics will enhance the risk of
hypercalcemia.
Hyperlipidemia - potential exacerbation of LDL elevation
Hyperphosphatemia - risk of meta